Research Article
Expression Analysis of Fibronectin Type III Domain-Containing (FNDC) Genes in Inflammatory Bowel Disease and Colorectal Cancer
Table 1
IBD patients’ characteristics.
| | IBD nonaffected | UC affected | CD affected |
| Number of subjects | 11 (4 CU, 7 CD) | 8 | 8 | Age, median years (range) | 45 (27-60) | 39 (26-54) | 32 (28-60) | Age at first diagnosis () | | | | Sex (male/female) | 6/5 | 7/1 | 3/5 | Localization | | | | Ileum | 5 | 0 | 4 | Ascending colon | 5 | 1 | 0 | Transverse colon | 6 | 4 | 1 | Descending colon | 5 | 1 | 1 | Sigmoid colon | 1 | 3 | 1 | Rectum | 4 | 1 | 1 | Mayo Score | | | | No activity (0-1) | 4 | 0 | NA | Mild disease (2-5) | 0 | 7 | NA | Moderate/severe disease (≥6) | 0 | 1 | NA | Harvey-Bradshaw Index | | | | Remission (<5) | 4 | NA | 4 | Mild disease (5-7) | 3 | NA | 3 | Moderate disease (8-16) | 0 | NA | 1 | Severe disease (>16) | 0 | NA | 0 | Montreal classification | | | | E1, E2, E3 | 0/1/3 | 0/3/5 | NA | A1, A2, A3 | 0/6/1 | NA | 0/7/1 | L1, L2, L3, L4 | 1/3/3/0 | NA | 1/4/3/0 | B1, B2, B3, B3p | 1/4/1/1 | NA | 1/4/1/2 | Medication | | | | No | 0 | 0 | 0 | 5-ASA | 2 | 5 | 1 | Corticosteroids | 2 | 2 | 2 | Immunosuppressives | 2 | 2 | 0 | Biologicals | 9 | 3 | 6 | Small molecule drugs | 0 | 0 | 1 | As combination | 4 | 3 | 2 | Laboratory findings () | | | | Erythrocytes (1012/L) | | | | Leukocytes (109/L) | | | | Thrombocytes (109/L) | | | | Hemoglobin (g/dL) | | | | CRP (mg/L) | | | | Sodium (mmol/L) | | | | Potassium (mmol/L) | | | |
|
|
Each column lists characteristics for all patients contributing with samples to the corresponding sample group. Abbreviations: E1: ulcerative proctitis; E2: left-sided UC; E3: pancolitis; A1: below 16 y; A2: between 17 and 40 y; A3: above 40 y; L1: ileal; L2: colonic; L3: ileocolonic; L4: isolated upper disease; B1: nonstricturing, nonpenetrating; B2: stricturing; B3: penetrating; B3p: perianal disease; 5-ASA: 5-aminosalicylic acid; CRP: C-reactive protein.
|